[ad_1]
SAN DIEGO, CA, Sept. 21, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical firm growing proprietary cannabinoid-derived molecules to deal with ailments with vital unmet want, introduced at this time its analysis associate, the College of Mississippi will current late-breaking preclinical knowledge evaluating completely different nanoemulsion formulations of its prodrug of tetrahydrocannabinol (THC), THCVHS, along with the prevalence of THCVHS, in decreasing intraocular stress in dutch belted rabbits when co-administered with netarsudil, a rho-kinase inhibitor, on the 2021 American Affiliation of Pharmaceutical Scientists Assembly (AAPS) PharmSci 360 being held October 17 -20, 2021, on the Pennsylvania Conference Heart in Philadelphia, Pennsylvania.
Particulars of late-breaking poster shows:
Title: IOP Profile in Dutch Belted Rabbits Following Topical Software of ∆9-Tetrahydrocannabinol-Valine-Hemisuccinate (THC-VHS, NB1111) Nanoemulsion Formulations
Poster quantity: M0930-06-33
Date: Monday, October 18, 2021 at 9:30AM – 10:30AM ET
Title: Co-administration of ∆9-Tetrahydrocannabinol-Valine-Hemisuccinate (THC-VHS, NB1111) and Netarsudil, a Rho-Kinase Inhibitor, Produces Superior IOP Decreasing Exercise in Dutch Belted Rabbits
Poster quantity: T0930-06-33
Date: Tuesday, October 19, 2021 at 9:30AM – 10:30AM ET
Full abstracts can be found on-line at www.aaps.org. Posters will probably be obtainable on Skye’s web site following the shows.
Concerning the College of Mississippi
The College of Mississippi, the state’s flagship college, is among the many elite group of R-1: Doctoral Universities – Highest Analysis Exercise within the Carnegie Classification. The college has a protracted historical past of manufacturing leaders in public service, teachers, analysis, and enterprise. Its 15 tutorial divisions embody a significant medical college, nationally acknowledged faculties of accountancy, legislation and pharmacy, and an honors school acclaimed for a mix of educational rigor, experiential studying, and alternatives for neighborhood motion. Over 50 years in the past, the college was awarded the primary federal authorities contract to domesticate hashish for analysis.
About Skye Bioscience
Skye Bioscience Inc. is a biopharmaceutical firm unlocking the pharmaceutical potential of cannabinoids via the event of its proprietary cannabinoid-derived molecules to deal with ailments with vital unmet wants. The corporate’s lead program, THCVHS, is concentrated on treating glaucoma, the world’s main explanation for irreversible blindness. For extra info, please go to: www.skyebioscience.com.
CONTACT
Karam Takhar
VP, Company Improvement & Investor Relations
Electronic mail: ir@skyebioscience.com
Cellphone: (858) 410-0266
FORWARD LOOKING STATEMENTS
This press launch comprises forward-looking statements, together with statements relating to our product improvement, enterprise technique, timing of medical trials and commercialization of cannabinoid-derived therapeutics. Such statements and different statements on this press launch that aren’t descriptions of historic info are forward-looking statements which might be based mostly on administration’s present expectations and assumptions and are topic to dangers and uncertainties. If such dangers or uncertainties materialize or such assumptions show incorrect, our enterprise, working outcomes, monetary situation, and inventory value could possibly be materially negatively affected. In some instances, forward-looking statements might be recognized by terminology together with “anticipated,” “plans,” “objective,” “focus,” “goals,” “intends,” “believes,” “can,” “might,” “problem,” “predictable,” “will,” “would,” “might” or the damaging of those phrases or different comparable terminology. We function in a quickly altering setting and new dangers emerge occasionally. Because of this, it’s not attainable for our administration to foretell all dangers, nor can we assess the affect of all elements on our enterprise or the extent to which any issue, or mixture of things, might trigger precise outcomes to vary materially from these contained in any forward-looking statements the Firm might make. Dangers and uncertainties which will trigger precise outcomes to vary materially embody, amongst others, our capital assets, uncertainty relating to the outcomes of future testing and improvement efforts and different dangers which might be described within the Danger Components part of Skye’s most up-to-date annual or quarterly report filed with the Securities and Trade Fee. Besides as expressly required by legislation, Skye disclaims any intent or obligation to replace these forward-looking statements.
[ad_2]
Source link
